טוען...
Real World Experience with Tofacitinib in IBD at a Tertiary Center
BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...
שמור ב:
| הוצא לאור ב: | Dig Dis Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/ https://ncbi.nlm.nih.gov/pubmed/30734234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|